James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why the Amgen, Inc. (AMGN) Patent Case Is So Important

Amgen (AMGN) is pursuing a court case that will force the legal system to make a decision that will essentially become statute.

Why Qualcomm, Inc. (QCOM), JPMorgan Chase & Co. (JPM) and Arista Networks Inc (ANET) Are 3 of Today’s Worst Stocks

Arista Networks (ANET), JPMorgan Chase (JPM) and Qualcomm (QCOM) led Tuesday's bearish charge, for all the right reasons.

Square Inc (SQ) Stock Is Red-Hot for All the Right Reasons

Square stock has been red hot of late, and that has some investors worried. SQ investors need not worry though -- analysts have this one right.

Valeant Pharmaceuticals Intl Inc (VRX) Can’t Escape This Endless Pit

Valeant Pharmaceuticals (VRX) is in more debt than it can handle, and it doesn't have a potent enough portfolio to keep its head above water.

Biogen Inc (BIIB) Will Win a Battle, But Could Lose the War

Biogen (BIIB) has a new blockbuster drug in Spinraza, but BIIB stock holders shouldn't cheer yet. Its pricing is quickly developing enemies.